Organization
Giselle Sholler
14 clinical trials
Clinical trial
A Phase II Trial of Nifurtimox for Refractory or Relapsed Neuroblastoma or Medulloblastoma.Status: Completed, Estimated PCD: 2020-04-28
Clinical trial
A Phase II Study of Naxitamab Added to Induction Therapy for Subjects With Newly Diagnosed High-Risk NeuroblastomaStatus: Recruiting, Estimated PCD: 2026-09-01
Clinical trial
A Randomized, Phase I/II Trial of Irinotecan and Temozolomide Compared to Irinotecan and Temozolomide in Combination With TPI 287 in Patients With Primary Refractory or Early Relapsed NeuroblastomaStatus: Terminated, Estimated PCD: 2014-12-01
Clinical trial
NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)Status: Recruiting, Estimated PCD: 2028-02-01
Clinical trial
A Phase II Preventative Trial of DFMO (Eflornithine HCl) as a Single Agent in Patients With High Risk Neuroblastoma in RemissionStatus: Completed, Estimated PCD: 2018-03-27
Clinical trial
A Phase I/II Trial of TPI-287 in Patients With Refractory or Recurrent Neuroblastoma and MedulloblastomaStatus: Terminated, Estimated PCD: 2014-12-01
Clinical trial
Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory NeuroblastomaStatus: Recruiting, Estimated PCD: 2028-10-01
Clinical trial
Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory MedulloblastomaStatus: Recruiting, Estimated PCD: 2028-03-01
Clinical trial
A Phase I Trial of Tolcapone Alone and in Combination With Oxaliplatin in Patients With Relapsed or Refractory NeuroblastomaStatus: Terminated, Estimated PCD: 2019-07-01
Clinical trial
A Study Using Molecular Guided Therapy With Induction Chemotherapy Followed by a Randomized Controlled Trial of Standard Immunotherapy With or Without DFMO Followed by DFMO Maintenance for Subjects With Newly Diagnosed High-Risk NeuroblastomaStatus: Recruiting, Estimated PCD: 2030-09-01
Clinical trial
A Phase I Trial for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With EtoposideStatus: Completed, Estimated PCD: 2014-10-01
Clinical trial
A Phase I/II Trial of DFMO in Combination With Bortezomib in Patients With Relapsed or Refractory NeuroblastomaStatus: Completed, Estimated PCD: 2024-01-19
Clinical trial
A Phase II, Open-label, Multi-center Study of Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma.Status: Terminated, Estimated PCD: 2015-10-01